Literature DB >> 6475891

Strategies to improve compliance with narcotic antagonists.

T R Kosten, H D Kleber.   

Abstract

The pharmacologic promise of naltrexone has not been matched by therapeutic usefulness. Plagued by difficulties in the induction period and very high dropout, the drug remains limited to a very small segment of the opiate-addited population. Some programs have managed, however, to substantially improve on these problems and such strategies will be discussed. The paper will look at the different problems raised during the high dropout periods of induction, the first month of stabilization, and the later stages of maintenance. It will then focus on methods to deal with these problems. Strategies examined will include among others individual and group counseling, family and couples' therapy, and contingency contracting. Strengths and weaknesses of each of these both from our own 7 years of experience and in the literature will be examined.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6475891     DOI: 10.3109/00952998409002784

Source DB:  PubMed          Journal:  Am J Drug Alcohol Abuse        ISSN: 0095-2990            Impact factor:   3.829


  13 in total

Review 1.  Opioid detoxification and naltrexone induction strategies: recommendations for clinical practice.

Authors:  Stacey C Sigmon; Adam Bisaga; Edward V Nunes; Patrick G O'Connor; Thomas Kosten; George Woody
Journal:  Am J Drug Alcohol Abuse       Date:  2012-03-12       Impact factor: 3.829

2.  Human behavioral pharmacology, past, present, and future: symposium presented at the 50th annual meeting of the Behavioral Pharmacology Society.

Authors:  Sandra D Comer; Warren K Bickel; Richard Yi; Harriet de Wit; Stephen T Higgins; Galen R Wenger; Chris-Ellyn Johanson; Mary Jeanne Kreek
Journal:  Behav Pharmacol       Date:  2010-07       Impact factor: 2.293

3.  Depot naltrexone: antagonism of the reinforcing, subjective, and physiological effects of heroin.

Authors:  Maria A Sullivan; Suzanne K Vosburg; Sandra D Comer
Journal:  Psychopharmacology (Berl)       Date:  2006-09-14       Impact factor: 4.530

4.  Depot naltrexone: long-lasting antagonism of the effects of heroin in humans.

Authors:  Sandra D Comer; Eric D Collins; Herbert D Kleber; Elie S Nuwayser; James H Kerrigan; Marian W Fischman
Journal:  Psychopharmacology (Berl)       Date:  2001-11-01       Impact factor: 4.530

5.  Naltrexone treatment for opioid dependence: does its effectiveness depend on testing the blockade?

Authors:  Maria A Sullivan; Adam Bisaga; John J Mariani; Andrew Glass; Frances R Levin; Sandra D Comer; Edward V Nunes
Journal:  Drug Alcohol Depend       Date:  2013-07-01       Impact factor: 4.492

Review 6.  Current and potential pharmacological treatment options for maintenance therapy in opioid-dependent individuals.

Authors:  Jeanette M Tetrault; David A Fiellin
Journal:  Drugs       Date:  2012-01-22       Impact factor: 9.546

7.  Injectable, sustained-release naltrexone for the treatment of opioid dependence: a randomized, placebo-controlled trial.

Authors:  Sandra D Comer; Maria A Sullivan; Elmer Yu; Jami L Rothenberg; Herbert D Kleber; Kyle Kampman; Charles Dackis; Charles P O'Brien
Journal:  Arch Gen Psychiatry       Date:  2006-02

8.  Cocaine vaccine for the treatment of cocaine dependence in methadone-maintained patients: a randomized, double-blind, placebo-controlled efficacy trial.

Authors:  Bridget A Martell; Frank M Orson; James Poling; Ellen Mitchell; Roger D Rossen; Tracie Gardner; Thomas R Kosten
Journal:  Arch Gen Psychiatry       Date:  2009-10

Review 9.  The use of incentives to reinforce medication adherence.

Authors:  Anthony DeFulio; Kenneth Silverman
Journal:  Prev Med       Date:  2012-05-02       Impact factor: 4.018

Review 10.  The neurobiology of opioid dependence: implications for treatment.

Authors:  Thomas R Kosten; Tony P George
Journal:  Sci Pract Perspect       Date:  2002-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.